|
11 Nov 2019 |
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
|
|
11 Nov 2019 |
TenNor Therapeutics Reported Phase II Top-Line Results for TNP-2092
|
|
11 Nov 2019 |
Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965
|
|
11 Nov 2019 |
Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science Session
|
|
11 Nov 2019 |
ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer
|
|
11 Nov 2019 |
Genentech’s Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy
|
|
09 Nov 2019 |
Aligos Therapeutics Presents Strong Chronic Hepatitis B Drug Candidate Portfolio at The Liver Meeting® 2019
|
|
09 Nov 2019 |
Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019
|
|
09 Nov 2019 |
Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
|
|
09 Nov 2019 |
FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis in Healthy Adult Subjects
|
|
08 Nov 2019 |
Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting
|
|
08 Nov 2019 |
AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia
|
|
08 Nov 2019 |
Daiichi Sankyo Announces Positive Results from ESAX-DN Phase 3 Study in Japan of Esaxerenone in Patients with Diabetic Nephropathy
|
|
08 Nov 2019 |
Inflazome Progresses Two Drugs Into Clinical Trials
|
|
08 Nov 2019 |
Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
|
|
08 Nov 2019 |
Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials
|
|
07 Nov 2019 |
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
|
|
06 Nov 2019 |
Targeting RNA with Small Molecules to Drug the Undruggable: new report analyzes companies, investors, partnerships, technologies and targets from an industry perspective
|
|
06 Nov 2019 |
Urania Therapeutics closes a €3.5M initial seed round
|
|
06 Nov 2019 |
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia
|
|
06 Nov 2019 |
eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
|
|
05 Nov 2019 |
EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer
|
|
05 Nov 2019 |
RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults
|
|
05 Nov 2019 |
Termination of project regarding ROR-gamma
|
|
04 Nov 2019 |
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
|
